

Matthew S. Benz, MD David M. Brown, MD Eric Chen, MD Richard H. Fish, MD
Christopher R. Henry, MD Rosa Y. Kim, MD James C. Major, Jr, MD PhD Ronan E. O'Malley, MD
Amy C. Scheffler, MD Ankoor R. Shah, MD Tien P. Wong, MD Charles C. Wykoff, MD PhD



M. Lance Patton
General Manager, Ophthalmology Division **Optos, Inc**
67 Forest Street
Marlborough, MA 01752

Dear Mr. Patton,


I first experienced optomap technology while conducting investigational trials for diabetes and retinal vein occlusion. The Optos device quickly became the preferred tool during this study as we discovered early on that the ultra widefield optomap imaging revealed so much more about the disease processes than we were able to acquire via traditional fundus photography. Subsequently in our practice, optomap moved from research tool, to a critical component of our daily exam and patient management process.

We are a large retinal practice in South Texas with numerous offices in populations with high incidences of diabetes. I am surprised daily by the amount of diabetic retinopathy, capillary non-perfusion and new disease that I find utilizing optomap. It shows me pathology that I would have difficulty seeing on standard clinical examination. I have found the UWF FA to be particularly valuable in helping me see emergent retinal changes facilitating earlier treatment in these patients before hemorrhages, traction and detachment occur.

Optomap is arguably even more valuable in patient education. The eye is essentially the canary in the coalmine and with one optomap image I can convey for a diabetic patient that what they see occurring in their eye, is also occurring in their systemic vasculature. One optomap can often impart the kind of critical information that had remained intangible through previous exams and clinical communications.

The prevalence of diabetes is increasing, and I believe that UWF angiography is essential for me to do what is best for my patients. After years of utilizing optomap and finding more pathology earlier, I feel I would be handicapped without the technology.

At this point you have a great product that has been well-vetted and optimized with a smaller footprint and better resolution centrally and in the far periphery. Optomap is an amazing tool - anyone who uses it for any length of time will discover, as I have, that they cannot live without it. With optomap technology one gets the best of both worlds, a great view of the central pole and the eye-opening experience of acquiring far peripheral views of the retina. For patient care and education, as well as for the betterment of understanding diseases, optomap is well worth the investment.

Sincerely,


David M. Brown, M.D.
Director of Clinical Research